Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for NGS-MRD Relapsed B-ALL Post-Transplant
NCT06504186Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
Open-label, single-arm trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Disease-Free Survival at 3 years and Recurrence Rate at 3 years. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06504186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504186.